Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis is currently trading at a 6.75% free cash flow yield. The FCF is higher than the net income due to the amortization of intangibles.

Novartis Hikes Its Dividend Again, Now Yields 3.8%

BHP Billiton

Service Corp

When a company's return on equity (ROE) ratio outperforms most of its peers, it indicates the company has been very efficient in generating earnings.

A Trio of High Return on Equity Stock Picks to Consider

EAST HANOVER, N.J., Feb. 16, 2021 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to reduce the risk of cardiovascular death and hospitalization for heart failure...

Novartis Entresto® granted expanded indication in chronic heart failure by FDA

GlaxoSmithKline

Basel, February 11, 2021 – Sandoz, a Novartis division, has signed an agreement to acquire GSK's cephalosporin antibiotics business, reinforcing its leading global position in antibiotics.

Sandoz announces agreement to acquire GSK's cephalosporin antibiotics business, reinforcing its leading global position in antibiotics

Novartis' (NVS) asciminib gets Breakthrough Therapy tag by the FDA for the treatment of adult patients with Ph+ CML in chronic phase, previously treated with two or more tyrosine kinase inhibitors.

Novartis (NVS) Gets Breakthrough Therapy Tag for Leukemia Drug

BeiGene

Week In Review: Matridx Raises $32 Million For AI/CRISPR-Cas Pathogen Metagenomics Diagnostic Devices

The digital press release with multimedia content can be accessed here:

Novartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis

Novartis (NVS) reports dismal fourth-quarter results as the pandemic affected sales. The outlook for 2021 also indicates challenges ahead.

Novartis (NVS) Misses on Q4 Earnings, Issues Grim 2021 Outlook

Novartis AG (NVS) CEO Vas Narasimhan on Q4 2020 Results - Earnings Call Transcript

Seelos Therapeutics

Allogene Therapeutics Inc

Selecta Biosciences

Allogene Therapeutics (NASDAQ: ALLO) shares are trading higher Tuesday after Stifel upgraded the stock from Hold to Buy and raised its price target from $33 to $43 per share. Allogene is a U.S.-based clinical-stage immuno-oncology company.

Why Novartis, Seelos Therapeutics And More Are Moving Today

Novartis stock toppled Tuesday after the drug company said it expects the coronavirus pandemic to weigh on prescription sales until mid-2021. Shares remained above a buy point, however.

Novartis Slammed: Expects Covid To Impact Drug Sales Until Mid-2021

The Swiss pharmaceutical company's stock slipped on Tuesday, as it offered cautious guidance.

Novartis Warns Covid-19 Sales Impact Will Last Until Mid 2021

Shares of Novartis (NYSE:NVS) decreased 3.8% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 1.52% over the past year to $1.34, which missed the estimate of $1.36.

Novartis: Q4 Earnings Insights

Novartis Chief Executive Vas Narasimhan on Tuesday renewed his commitment to his Sandoz generic unit where sales growth in 2020 stagnated due to reduced hospital stays during the COVID-19 pandemic.

Novartis CEO renews commitment to Sandoz generics unit

Basel, January 26, 2021 - commenting on 2020 results, Vas Narasimhan, CEO of Novartis, said: “Novartis delivered a solid performance in 2020 across our strategic priorities, despite the challenges of COVID-19. Operationally, we grew sales and continued to improve core operating margins for Innovative Medicines. We advanced our next wave of medicines achieving a number of new approvals highlighted by Kesimpta in the US, Leqvio and Zolgensma in the EU and progressed our broad and deep mid-stage pipeline of first-in-class medicines. Looking ahead, we are confident that the progress we have made on our strategic priorities as a focused medicines company, will result in top and bottom line growth through 2025.”

Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.

Novartis (NYSE:NVS) announces its next round of earnings this Tuesday, January 26. Here is Benzinga's look at Novartis's Q4 earnings report.

Novartis's Earnings Outlook

BeiGene out-licensed ex-China rights for tislelizumab, its China-approved anti-PD-1 antibody, to Novartis in a $2.2 billion agreement. Inmagene in-licensed global rights to four novel pre-clinical immunological candidates from Hutchison China MediTech in a deal that has a potential value of $920 million.

Week In Review: BeiGene Signs $2.2 Billion Deal With Novartis For PD-1

Esperion Therapeutics

VBI Vaccines

Esperion Therapeutics (NASDAQ: ESPR) shares are trading lower after Bank of America Securities downgraded the stock from Buy to Neutral and announced a price target of $35 per share. Esprit Holdings is an international fashion brand whose operations include Retail, Wholesale and Licensing.

Why Novartis, BioVie, Esperion And VBI Are Moving Today

Novartis (NVS) gets Breakthrough Therapy designation by the FDA for ligelizumab for the treatment of chronic spontaneous urticaria.

Novartis' (NVS) Ligelizumab Gets Breakthrough Therapy Status

Bristol-Myers

Johnson & Johnson

Invitae

Roche Holding AG

Invitae Nabs Bristol Myers Squibb, J&J, Novartis, and Roche for Acute Myeloid Leukemia Project

Novartis (NVS) in-licenses BeiGene's anti-PD-1 monoclonal antibody, tislelizumab, in major markets outside of China.

Novartis (NVS) In-Licenses Anti-PD-1 Antibody from BeiGene

Beigene stock jumped Tuesday on a cancer drug development deal with Novartis worth up to $2.2 billion, as Vir Biotechnology also announced a hepatitis B tie-up with Gilead Sciences. The post Beigene Surges Closer To Breakout On $2.2 Billion Deal With Novartis appeared first on Investor's Business Daily.

Beigene Surges Closer To Breakout On $2.2 Billion Deal With Novartis

Novartis AG (NVS) CEO Vas Narasimham Presents at 39th Annual J.P. Morgan Virtual Healthcare Conference (Transcript)

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene and Novartis enter into a collaboration to develop, manufacture and commercialize tislelizumab, BeiGene's anti-PD-1 antibody.

BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab

Basel, January 11, 2021 — Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene, Ltd. in major markets outside of China, accelerating the potential for Novartis to enter the large and growing checkpoint inhibitor field. Tislelizumab is an anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells.

News for Novartis Stock (NVS)